The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. [electronic resource]
Producer: 20031224Description: 442-8 p. digitalISSN:- 0344-5704
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Blotting, Western
- Cell Line, Tumor
- Cell Survival -- drug effects
- Colonic Neoplasms -- pathology
- DNA Adducts -- drug effects
- Dose-Response Relationship, Drug
- Drug Evaluation, Preclinical
- Gefitinib
- HT29 Cells
- Humans
- Inhibitory Concentration 50
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Precipitin Tests
- Quinazolines -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.